AgeX Therapeutics, Inc. (AGE) News

AgeX Therapeutics, Inc. (AGE): $0.37

0.01 (-2.89%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add AGE to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#341 of 495

in industry

Filter AGE News Items

AGE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest AGE News From Around the Web

Below are the latest news stories about AGEX THERAPEUTICS INC that investors may wish to consider to help them evaluate AGE as an investment opportunity.

Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer

Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TM drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics, today announced Serina has entered into a License Agreement under which Pfizer Inc. wil

Yahoo | November 17, 2023

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

ALAMEDA, Calif., November 14, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023.

Yahoo | November 14, 2023

Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement

HUNTSVILLE, Ala. & ALAMEDA, Calif., August 30, 2023--Serina Therapeutics, Inc. ("Serina"), a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson’s Disease and other neurological diseases, entered into a merger agreement with AgeX Therapeutics, Inc. (NYSE American: AGE) ("AgeX") on August 29, 2023, under which Serina will merge with a wholly-owned subsidiary of AgeX in an all-stock transaction. The combined company will continue u

Yahoo | August 30, 2023

AgeX Therapeutics Reports Second Quarter 2023 Financial Results

ALAMEDA, Calif., August 14, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023.

Yahoo | August 14, 2023

AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock

ALAMEDA, Calif., July 24, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 24, 2023, AgeX issued to Juvenescence Limited 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loa

Yahoo | July 24, 2023

AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock

ALAMEDA, Calif., July 21, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 21, 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 M

Yahoo | July 21, 2023

AgeX Therapeutics Announces Appeal of NYSE American Determination

ALAMEDA, Calif., May 23, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on May 17, 2023 it received a notice from the staff of the NYSE American (the "Exchange") indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i), (ii) and (iii)

Yahoo | May 23, 2023

AgeX Therapeutics Reports First Quarter 2023 Financial Results

ALAMEDA, Calif., May 12, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023.

Yahoo | May 12, 2023

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

ALAMEDA, Calif., April 26, 2023--AgeX Therapeutics , Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April 20, 2023 it received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has st

Yahoo | April 26, 2023

AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results

ALAMEDA, Calif., March 31, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022.

Yahoo | March 31, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!